STAT October 28, 2024
At issue is whether one company copied the technology of another
For several years, a rivalry has been brewing between two high-profile gene-editing companies. On one hand is Prime Medicine, built on prime editing, a technology out of David’s Liu lab at the Broad Institute for making small insertions, deletions, and single-letter changes to DNA. On the other is Tessera Therapeutics, a biotech launched by Flagship Pioneering, the VC behind Moderna,...
Today's Sponsors
Today's Sponsor